Background: Prodromal bullous pemphigoid (PBP) can be difficult to diagnose. Early recognition in its early stages may decrease the morbidity and progression of the disease. Clinical presentations and current treatments available for PBP will be described.
Methods: A retrospective review was performed on 53 patients diagnosed with PBP.
Results: Overall, the average disease duration of PBP was 11.8 months. The average age of presentation of PBP was 70.8 years. The most common presentations were urticaria-like plaques (67.9%), eczema-like lesions (11.3%), and dermatitis herpetiformis-like lesions (9.4%). The majority of patients responded well to low doses of systemic corticosteroids, tetracycline, and/or high potency topical corticosteroids.
Conclusions: Patients with PBP tend to be in their sixth or early seventh decade of life and, on average, the duration of disease is 1 year. The most common presentation of disease is urticaria-like plaques.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2004.02457.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EDI-OCT as an auxiliary examination for the differential diagnosis of bullous CSC and Vogt-Koyanagi-Harada: A case report.
Photodiagnosis Photodyn Ther
April 2024
Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
A 46-year-old male patient visited our clinic with a complaint of blurred vision in the right eye accompanied by headache and insomnia. The fundus examination showed three bullous retinal detachments in the right eye. Considering the prodromal symptoms and other fundus characteristics such as vitreous cells in the posterior pole and multifocal fluorescence leakages on fundus fluorescein angiography (FFA), initial diagnosis was considered as Vogt-Koyanagi-Harada (VKH).
View Article and Find Full Text PDFLichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report.
SAGE Open Med Case Rep
December 2023
Dermatology Department, Manuel Gea González General Hospital, Tlalpan, CDMX, Mexico.
Nivolumab (PD-1 inhibitor) and ipilumumab (CTLA-4 inhibitor) are recently approved checkpoint inhibitors for treatment of non-small cell lung cancer. Immune-related adverse events related to the usage of checkpoint inhibitors are growing with their popularity. We present the case of a patient in combination treatment of nivolumab and ipilimumab who developed a lichenoid drug reaction, notable because it worsened to a bullous lichenoid drug reaction.
View Article and Find Full Text PDFBullous pemphigoid associated with prodromal-phase by repeated COVID-19 vaccinations.
J Dermatol
January 2024
Department of Dermatology, Kurume University School of Medicine, Fukuoka, Japan.
Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches.
Front Med (Lausanne)
August 2023
Cancer Vaccine and Immune Cell Therapy Core Laboratory, Chang Gung Memorial Hospital, Chang Gung Immunology Consortium, Taoyuan, Taiwan.
Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases and mainly affects an elderly population with multi-morbidity. Due to the frailty of many BP patients, existing treatment options are limited. The blisters associated with BP result from IgG and IgE autoantibodies binding to the central components of hemidesmosome, BP180, and BP230, stimulating a destructive inflammatory process.
View Article and Find Full Text PDFOdynophagia as the first manifestation of toxic epidermal necrolysis.
BMJ Case Rep
November 2022
Otorhinolaryngology, Hospital Universitario Doctor Peset, Valencia, Spain
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are infrequent mucocutaneous diseases, rapidly progressive and life-threatening. The clinical aspects and the management of TEN are exposed following a case.A man in his 40s presented to the emergency department with severe odynophagia, poor general condition and fever.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!